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Abstract
Background: Activation of Ras or Raf contributes to tumorigenesis of melanoma. However,
constitutive Raf activation is also a characteristic of the majority of benign melanocytic nevi and high
intensity signaling of either Ras or Raf was found to induce growth inhibition and senescence rather
than transformation. Since the chromosome 3p kinase (3pK)) is a target of the Ras/Raf/Mek/Erk
signaling pathway which antagonizes the function of the oncogene and anti-differentiation factor
Bmi-1, 3pK may function as a tumor suppressor in tumors with constitutive Ras/Raf activation.
Consequently, we tested whether inactivating 3pK mutations are present in melanoma.
Methods: 30 metastatic melanoma samples, which were positive for activating mutations of either
BRaf or NRas, were analyzed for possible mutations in the 3pk gene. The 10 coding exons and their
flanking intron sequences were amplified by PCR and direct sequencing of the PCR products was
performed.
Results: This analysis revealed that besides the presence of some single nucleotide polymorphisms
in the 3pk gene, we could not detect any possible loss of function mutation in any of these 30
metastatic melanoma samples selected for the presence of activating mutations within the Ras/Raf/
Mek/Erk signaling pathway.
Conclusion: Hence, in melanoma with constitutively active Ras/Raf inactivating mutations within
the 3pk gene do not contribute to the oncogenic phenotype of this highly malignant tumor.
Background
Transcriptional repressors of the Polycomb group (PcG)
are part of the cellular epigenetic machinery [1]. The PcG
protein Bmi-1 was described as an oncogene in murine
lymphomas, which acts via repression of the ink4A locus
[2]. Its implication in human tumorigenesis is suggested
by the finding that it is amplified or overexpressed in sev-
eral human cancers [3-5] Bmi-1 was shown to be an anti-
differentiation factor, e.g. its overexpression extents the
replicative life span of human fibroblasts by suppressing
the p16-dependent senescence pathway [6]. In addition,
Bmi-1 is a self-renewal factor for hematopoietic and neu-
ral stem cells [7-9].
The gene of the chromosome 3p kinase (3pK; also known
as Mapkap Kinase 3) was isolated by analysis of the chro-
mosomal region 3p21.3 which is homozygously deleted
in two cancer cell lines [10]. Very recently we found that
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3pK interacts with and phosphorylates Bmi-1 thereby
diminishing Bmi-1 chromatin association [11]. Overex-
pression of 3pK has growth suppressive properties in var-
ious cell lines, which can be overcome by Bmi-1
overexpression (Voncken and Rapp, unpublished obser-
vation). It should be noted, that 3pK is a target of the clas-
sical mitogenic Ras/Raf/Mek/Erk signaling pathway and is
activated by phosphorylation through Erk [12].
It is well established that activation of the Ras/Raf/Mek/
Erk pathway contributes to tumorigenesis and melanoma
is the tumor with the highest prevalence of activating
mutations within the braf  gene [13-15]. On the other
hand activating BRaf mutations are present in the major-
ity of benign melanocytic lesions and high intensity sign-
aling of either Ras or Raf were found to induce growth
inhibition and senescence rather than transformation
[16]. These observations may be explained by an activa-
tion of the 3pK/Bmi-1/Ink4A branch. Thus, inactivating
3pK mutation may be part of the neoplastic transforma-
tion of tumors with activated Ras or Raf such as
melanoma.
Materials and methods
Tumor material
Paraffin embedded tumor samples from 30 metastatic
melanomas were obtained by surgical excision. All tumors
have undergone routine histology for diagnosis. The
immediately adjacent slides from the blocks were used for
DNA extraction. Informed consent was obtained from all
patients prior to any of these measures.
Polymerase chain reaction
Genomic DNA was isolated from paraffin embedded
tumor samples using a DNA Isolation Kit (Qiagen).
Applying conventional PCR on these templates let to fre-
quent drop outs not yielding the desired product. We
therefore applied Nested PCR protocols with a first 22
cycle PCR reaction (30 µl) followed by a second 35 cycle
PCR reaction (55 µl) in which 1 µl of the first reaction
served as template. The Cycles always consisted of 30 sec-
onds denaturing at 95°C, 30 seconds annealing followed
by 30 seconds elongation at 72°C. Primers and corre-
sponding annealing temperatures are given in table 1.
Sequencing
Samples were sequenced using BigDye™ Terminator Cycle
Sequencing Ready Reaction Kit (Applied Biosystems)
according to the manufacturer's manual, and analyzed on
an ABI PRISM 3100 Avant Genetic Analyzer. The
sequences were first analyzed by visual inspection, look-
ing for double peaks or untypical background signals.
Additionally alignments with the published genomic
sequence were performed using the DNAStar™ software.
Results and discussion
Previously we had analyzed a series of 200 melanoma
samples for the presence of activating mutations in BRaf
and NRas [17]. Out of these samples we choose a set of 30
metastatic melanomas of which 25 carried a BRaf (V599E,
V599R or V599K) and 5 an NRas mutation (Q61R or
Q61K). For these 30 samples we amplified the coding plus
adjacent intron sequences of the exons 2 to 11 and sub-
jected them to sequence analysis. To this end, no nucle-
otide exchange which would alter the amino acid
sequence of the 3pK protein was detected indicating that
the 3pKinase is not frequently affected by mutations in
metastatic melanoma with constitutively activated Ras/
Raf signaling pathway.
Table 1: Conditions of the nested PCR for the 10 coding exons of 
the 3pK gene. Primer sequences and the corresponding 
annealing temperatures are given.
Exon Primer Annealing
2 first PCR: ctcgcagcccagcccagttcag
gctacgcctcagtttccccatct
66°C
nested PCR: tctgggcgggactcactcttc
gctacgcctcagtttccccatct
66°C
3 first PCR: ggcctcagagcttatatgtttttg
gatgccgagggggtgtggag
63°C
nested PCR: ggcctcagagcttatatgtttttg
gtttcttgcccacccttgag
63°C
4 first PCR: ggcaggggcaagggtagg
agatgggaagactgagaggaaca
64°C
nested PCR: ctgaagcctgggcctatgatttg
agatgggaagactgagaggaaca
64°C
5 first PCR: ttgtgctggcctgttagactgtgt
aggctgggtgagaatgaaatgaga
67°C
nested PCR: cccgggatagagaacctggatag
aggctgggtgagaatgaaatgaga
67°C
6 first PCR: aggcccgggtctttttat
cccacgtcacccgcctccat
66°C
nested PCR: cacctgccttgcttccccttttgt
cccacgtcacccgcctccat
58°C
7 first PCR: ctttctcctcccccaacttcaca
cccaggcacatcccaggaat
66°C
nested PCR: ctttctcctcccccaacttcaca
ctccggactcccaggcacatc
66°C
8 first PCR: ggagtccggagggctggtattatt
gaggctcaagaaggttagg
59°C
nested PCR: actgctcccaccctatgccaaatg
gaggctcaagaaggttagg
59°C
9 first PCR: ggctgccctgtatgagttatct
gcagtgacaaagccaggtt
63°C
nested PCR: ggctgccctgtatgagttatct
aaagccaggttgtaggtgagg
63°C
10 first PCR: gtcccaggtgcctccagtttctaa
aagccccgtttcattgagga
60°C
nested PCR: ggagtagggggaaccagtgctgtc
aagccccgtttcattgagga
64°C
11 first PCR: gggggtgatggttcctaagg
cctcactcgggccaaccta
64°C
nested PCR: tgggcacagaggcagcacagg
cctcactcgggccaaccta
64°CJournal of Carcinogenesis 2005, 4:23 http://www.carcinogenesis.com/content/4/1/23
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An intronic single nucleotide polymorphism (SNP) was
detected 42 nucleotides downstream (in 3' direction) of
exon 4. Within the sequence GCAGGAGGATTCAGGGT-
GAG the last G was frequently altered to A. In two cases we
received only an A signal. In 13 cases we found hetero-
zygous A and G and in 15 cases only the published G was
present (Figure 1A, B and 1C). 160 nucleotides upstream
(in 5' direction) of exon 9 within the sequence GTT-
TCAAAACAAGAAATAG the first G was altered to an A in
all but one case (Figure 1D). Only in this one sample in
addition to the A signal a signal for a G was detectable
(Figure 1E). Because of the very rare appearance of the
published sequence we asked whether this alteration
might be a melanoma specific SNP. Therefore we ampli-
fied and sequenced this region from genomic DNA of 14
healthy donors. In all 14 cases we found G instead of A in
the corresponding position, demonstrating that this is the
preferential nucleotide in the german population.
The absence of inactivating mutations within the 3pk
gene, however, does not rule out the possibility that 3pK
function in these tumors might be affected by reduced
expression levels. For example, in uveal melanoma muta-
tions in the coding sequence of the tumor suppressor
Ink4A are very rare, but hypermethylation of its promoter
is a common cause of reduced Ink4a expression in these
tumors [18].
In a previous study we correlated the Ras/Raf mutational
status of 200 melanoma lesions with the the clinical
course; the presence of activating mutations within pri-
mary tumors did not impact the prognosis – a notion fur-
Sequence chromatographs of intronic sequences from the 3pK amplicons exon 4 (A, B and C) an exon 9 (D and E) Figure 1
Sequence chromatographs of intronic sequences from the 3pK amplicons exon 4 (A, B and C) an exon 9 (D 
and E). 42 nucleotides downstream of exon 4 either homozygously G or homozygously A or a heterozygous genotype was 
found. (A, B and C). 160 nucleotides upstream of exon 9 we found predominantly an A instead of the published G (D). Only in 
one case signals for G and A were detectable. (E).
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ther substantiated by the results of multivariate analysis
which revealed that for this patient cohort mutations in
the braf gene were not correlated with established markers
for bad prognosis such as tumor thickness or ulceration.
The presence of BRaf mutations in metastatic lesions,
however, was associated with poor prognosis, i.e. short-
ened survival from either the removal of the respective
metastases or clinical diagnosis of stage IV disease.
Because of this observation together with the fact that car-
cinogenesis is a multistage process one can assume that
additional genetic or epigenetic alterations are necessary
for the neoplastic transformation of melanocytic cells and
that in the absence of these alteration(s) the poor progno-
sis properties of activated BRaf are masked. In the present
study, we ruled out, that inactivating mutations of 3pk are
frequent events in metastatic melanoma with constitu-
tively activated Ras/Raf signaling pathway. Others tested a
possible tumor suppressor function of 3pK by ectopic
expression of 3pk in two cancer cell lines. This however
did not antagonize the tumorous growth of these cells in
Scid mice [19]. Therefore 3pK remains a canditate tumor
suppressor and its possible role in tumor development
needs further investigation.
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